Animab has successfully closed a EUR 10 million Series B funding round to support the commercialization of its innovative oral monoclonal antibody, Nanoprotec®, aimed at improving livestock health in Europe.

Target Information

Animab, a pioneering biotech company founded in 2020, is at the forefront of developing first-in-class oral antibody solutions for unmet needs in livestock production. The company’s flagship product, Nanoprotec®, is an oral monoclonal antibody designed to combat enterotoxigenic Escherichia coli (ETEC) infections in piglets, conditions that lead to severe diarrhea, poor growth, and high mortality rates. With over 60 million piglets affected yearly in the European Union, Nanoprotec® provides an antibiotic-free alternative to traditional disease control methods, aiming to enhance the health and efficiency of livestock farming.

Animab recently closed a successful EUR 10 million Series B funding round aimed at supporting the commercialization of Nanoprotec® in Europe. This follows the company’s exclusive distribution agreement with Huvepharma, highlighting a robust momentum towards bringing the product to market. With a regulatory filing set for the end of 2025 and a market launch anticipated by the end of 2026, Animab is positioning itself to make a significant impact in the livestock health sector.

Industry Overview

The livestock industry in Europe is increasingly challenged by concerns related to antimicrobial resistance (AMR), which poses severe risks to both animal and public health. With the growing awareness of antibiotic overuse in livestock, th